特立氟胺与富马酸二甲酯治疗复发缓解型多发性硬化全国队列比较
该全国队列研究纳入丹麦多发性硬化登记处2236例复发缓解型多发性硬化患者,比较特立氟胺与富马酸二甲酯的治疗效果和停药结局。结果显示富马酸二甲酯的年化复发率更低、无复发生存率更高、因疾病突破停药比例更低,扩展残疾状态量表评分恶化无差异。
要点
- 富马酸二甲酯组年化复发率0.09,特立氟胺组0.16,复发率比0.58(95%CI 0.46-0.73,P<0.001)。
- 富马酸二甲酯48个月无复发生存比例更高(P<0.05)。
- 因疾病突破停药比例:富马酸二甲酯10.2%,特立氟胺22.1%。
核心结论
- 富马酸二甲酯相比特立氟胺有更低的年化复发率、更高的无复发生存率和更低的因疾病突破停药发生率。
研究设计与样本
- 基于丹麦多发性硬化登记处的全国队列研究,纳入2236例起始特立氟胺或富马酸二甲酯治疗的复发缓解型多发性硬化患者,其中特立氟胺1469例、富马酸二甲酯767例。
- 采用倾向评分方法并校正临床基线变量,比较两组治疗效果结局。
主要发现
- 特立氟胺和富马酸二甲酯的年化复发率分别为0.16(95%CI 0.13-0.20)和0.09(95%CI 0.07-0.12)。
- 富马酸二甲酯/特立氟胺的复发率比为0.58(95%CI 0.46-0.73,P<0.001)。
- 富马酸二甲酯在48个月随访时无复发生存比例更高(P<0.05)。
- 扩展残疾状态量表评分恶化无差异。
- 因疾病突破停药比例:富马酸二甲酯10.2%(95%CI 7.6%-12.8%),特立氟胺22.1%(95%CI 19.2%-25.0%)。
关键数值与推荐
- 在708例有基线MRI T2病灶数量数据的亚组分析中,校正后年化复发率结果相似。
临床怎么用
- 对于复发缓解型多发性硬化患者,富马酸二甲酯在预防复发和减少因疾病突破停药方面可能优于特立氟胺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting. METHODS: We identified all patients starting TFL or DMF from the Danish Multiple Sclerosis Registry and compared on-treatment efficacy outcomes between DMF using TFL, adjusted for clinical baseline variables and propensity score-based methods. RESULTS: We included 2,236 patients in the study: 1,469 patients on TFL and 767 on DMF. Annualized relapse rates (ARRs) in TFL and DMF were 0.16 (95% confidence interval [CI] 0.13-0.20) and 0.09 (95% CI 0.07-0.12), respectively. Relapse rate ratio for DMF/TFL was 0.58 (95% CI 0.46-0.73, p < 0.001). DMF had a higher relapse-free survival proportion at 48 months of follow-up (p < 0.05). We observed no difference in Expanded Disability Status Scale score worsening. Discontinuations due to disease breakthrough were 10.2% (95% CI 7.6%-12.8%) and 22.1% (95% CI 19.2%-25.0%) for DMF and TFL, respectively. A subgroup analysis of ARRs in 708 patients with available baseline MRI T2 lesion amount reported similar results after adjustment. CONCLUSION: We found lower ARR, higher relapse-free survival, and lower incidence of discontinuation due to disease breakthrough on treatment with DMF compared with TFL. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with RRMS, DMF is more effective in preventing relapses and has lower discontinuation due to disease breakthrough compared with TFL.
引用
- Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study. Neurology. 2019. PMID: 30877188. doi:10.1212/WNL.0000000000007314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。